IMM.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 02:10):

Stats
Today's Volume	13.37M
Average Volume	1.50M
Market Cap	534.97M
EPS	$0 ( 2024-02-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.25
ATR14	$0.00200 (0.44%)

Volume Correlation

Long: 0.05 (neutral)

Short: 0.61 (weak)

Signal:(65.977) Neutral

Immutep Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immutep Ltd Correlation - Currency/Commodity

-0.65
( weak negative )

-0.73
( moderate negative )

0.00
( neutral )

-0.39
( neutral )

Immutep Ltd Financials

Annual	2022
Revenue:	$3.51M
Gross Profit:	$1.44M (41.19 %)
EPS:	$-0.0453

Q4	2022
Revenue:	$1.82M
Gross Profit:	$896 169 (49.23 %)
EPS:	$-0.0211

Q2	2022
Revenue:	$1.69M
Gross Profit:	$750 339 (44.52 %)
EPS:	$-0.0232

Q2	2019
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Immutep Ltd

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.